Think familiarity and convenience.

Think ANKTIVA^®.

ANKTIVA is the first FDA-approved immunotherapy designed to activate the body’s natural immune system to target and attack BCG-unresponsive non-muscle invasive bladder CIS (NMIBC CIS), potentially leading to a long duration of complete response up to 47+ months¹.

ANKTIVA is a Potent Immunostimulant that Unlocks Anti-tumor Activity and Unleashes Durable, Complete Responses.

ANKTIVA uniquely stimulates the body’s natural immune system by proliferating and activating natural killer cells, as well as cytotoxic and memory T cells to drive long-term immune memory and durable responses.

Primary Endpoint

Gauge graphic showing 62% complete response (CR) rate among study participants, biopsy-confirmed, n=77 (95% CI: 51-73%), with text explaining that their cancer was eliminated.

Duration of Response

Up to47+ Months58% (n=28) ≥12 months; 40% (n=19) ≥24 months; range: 0.0–47.0+ months¹+ Denotes an ongoing response.

Full Enrollment Follow-up

Duration of ResponseUp to53 MonthsSome patients remained NMIBC-free for over 4 years²

Diagram illustrating the "Triangle Offense" mechanism of ANKTIVA: a central triangle connecting three circles showing how it activates and proliferates Natural Killer cells (top), CD8+ Killer T cells (left), and Memory T cells (right), with arrows indicating synergy for durable benefit in bladder cancer treatment by killing cancer cells and enabling long-term immune recognition.

1. Anktiva (nogapendekin alfa inbakicept-pmln) prescribing information. ImmunityBio, 2024. 2. Chang, S. (2025, April 26-29). An Update on QUILT-3.032: Durable Complete Responses to NAI (ANKTIVA) Plus BCG Therapy in BCG-Unresponsive CIS With or Without Ta/T1 Papillary Disease and in Papillary Disease without CIS. [Conference Presentation]. AUA2025, Las Vegas, Nevada, United States.

Patient Stories

Read about patients who participated in the clinical trials for ANKTIVA

Justin’s Journey

An avid outdoorsman, Justin faced a challenging diagnosis of non-muscle invasive bladder cancer. After struggling with the side effects of his Bacillus Calmette-Guérin (BCG) treatment, he found renewed hope though his doctors' introduction to an immunotherapy for those who experienced a recurrence of NMIBC.

Learn More

Wayne’s Journey

Wayne has lived a rich life with his wife, two daughters, and three grandchildren. He describes himself as someone who “just likes people.” When he was first told, “you might have a tumor in your bladder,” he became very concerned, especially when he learned his first treatment with BCG wasn’t working. Wayne feels lucky that a friend told him about a clinical trial for patients like himself who were not cured by BCG alone.

Learn More

See All Stories

ANKTIVA Resources

Information for ANKTIVA

DATASHEET

ANKTIVA: How to Order

A step-by-step guide on how to order ANKTIVA, including product codes

Download PDF

VIDEO

Physicians' Journey

Listen to the physicians' journey with their patients using ANKTIVA.

Watch Video

See All Resources

Indication and Important Safety Information

INDICATION AND USAGE

ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

WARNINGS AND PRECAUTIONS

Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after a second induction course of ANKTIVA with BCG, reconsider cystectomy.

DOSAGE AND ADMINISTRATION

For lntravesical Use Only. Do not administer by subcutaneous or intravenous routes. Instill intravesically only after dilution. Total time from vial puncture to the completion of the intravesical instillation should not exceed 2 hours.

USE IN SPECIFIC POPULATIONS

Pregnancy: May cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.

ADVERSE REACTIONS

The most common (≥15%) adverse reactions, including laboratory test abnormalities, are increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills and pyrexia.

For more information about ANKTIVA, please see the Full Prescribing Information at www.anktiva.com.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088. You may also contact lmmunityBio at 1-877-ANKTIVA (1-877-265-8482)

ANKTIVA is a Novel Treatment for NMIBC CIS Patients Unresponsive to BCG

For more information, please call 1-877-ANKTIVA

Think ANKTIVA®.